Recordati Industria Chimica e Farmaceutica (OTCMKTS:RCDTF) Hits New 52-Week Low – Time to Sell?

Recordati Industria Chimica e Farmaceutica S.p.A. (OTCMKTS:RCDTF) shares hit a new 52-week low during trading on Thursday . The company traded as low as $52.25 and last traded at $52.25, with a volume of 0 shares. The stock had previously closed at $52.25.

Wall Street Analyst Weigh In

RCDTF has been the subject of a number of recent research reports. Barclays raised Recordati Industria Chimica e Farmaceutica to a “strong sell” rating in a report on Tuesday, October 22nd. Royal Bank of Canada raised Recordati Industria Chimica e Farmaceutica to a “hold” rating in a research note on Monday, October 7th.

Recordati Industria Chimica e Farmaceutica Price Performance

The company has a 50-day moving average price of $52.25 and a 200-day moving average price of $51.92. The company has a debt-to-equity ratio of 0.73, a quick ratio of 0.95 and a current ratio of 1.36. The firm has a market capitalization of $10.78 billion, a P/E ratio of 26.13 and a beta of 0.33.

About Recordati Industria Chimica e Farmaceutica

Recordati Industria Chimica e Farmaceutica S.p.A., together with its subsidiaries, engages in the research, development, manufacture, and marketing of pharmaceuticals worldwide. The company operates through Specialty and Primary Care and Rare Diseases segments. Its product pipeline includes REC 0559 which is in Phase II for the treatment of Neurotrophic Keratitis; REC 0545 for acute decompensation in maple syrup urine diseases; ISTURISA for endogenous Cushing's syndrome; and CYSTADROPS, an corneal cystine deposits in patients with cystinosis.